Magic™ Anti-SAA (aa 23-29) monoclonal antibody

AA7204-T4 aluminum alloy plates were welded by friction stir welding (FSW) , and the effect of post-weld heat treatment on the microstructure and mechanical properties of the FSW joints were studied. The results show that the average grain size (AGS) and recrystallization fraction of nugget zone(NZ) are 4. 7 mu m and 81. 9% in as-welded(AW) treatment, 4. 8 mu m and 82. 4% under the post-weld artificial aging (AA) treatment, 5. 9 mu m and 86. 5% under the heat treatment of solid solution followed by artificial aging(SAA), respectively. The grain structure of NZ is not obviously affected by AA treatment, and the AGS and recrystallization fraction of NZ increase by 25. 5% and 5.6% under SAA treatment. The ultimate tensile strength (UTS) of the FSW joints are 296. 6, 318.2, 357.4 MPa under the heat treatments of AW, AA and SAA, respectively. The improvement of the mechanical properties of FSW joints is limited by AA treatment, while that can be effectively improved by SAA treatment which leads to the welding coefficient reaching 92. 0%. Additionally, the microcracks tend to generate on the "S" line under the effect of water quenching after solid solution, which would lead to the fracture location at this zone and the serious decrease of the elongation.

Survival rates for sarcoma patients have plateaued in the past few decades and remain especially grim for those with recurrent or metastatic disease. This has prompted investigation into novel immunotherapies for sarcomas, especially after their recent and well-recognized successes in other cancers. One such modality, the Chimeric Antigen Receptor (CAR) T Cell therapy, has shown promising results in treating B-cell lymphoma and acute lymphoblastic leukemia. This novel therapy functions by fusing a specific antibody derived single-chain variable fragment (scFv) with a T-cell which recognizes a specific tumor-associated antigen (TAA). Several sarcoma-associated antigens (SAA) amenable to CAR-T cell treatment have recently emerged with encouraging results. These include human epidermal growth factor receptor 2 (HER2), disialoganglioside (GD2), interleukin 11 Receptor Subunit Alpha (IL-11RA), fibroblast activation protein (FAP), B7-H3, CD44v6, insulin-like growth factor 1 receptor (IGF-1R), and tyrosine kinase orphan-like receptor 1 (ROR1). Given the limitations of current medical therapies, novel treatment strategies are urgently needed. As a sarcoma treatment modality, CAR-T cell therapy is highly promising and continues to draw interest especially as new clinical trials emerge. Here we review recent breakthrough CAR-T cell studies in sarcoma, the targets which define them, and approaches to minimizing host cytotoxicity.